Finished
A Study of Effects of Fesoterodine in Men at High Risk for Overactive Bladder/Detrusor Overactivity Post Robotic-Assisted Lap. Prostatectomy
NCT01661166 · Abramson Cancer Center at Penn Medicine · Updated 28 April 2020
- What is being tested
- Fesoterodine; Placebo oral tablet
- For
- Prostate Adenocarcinoma
- Kind of study
- Tests a treatment or device on volunteers. Phase 4.
- Who can join
- Ages 30 years to 90 years. About 3 people. The full rules are on the registry page.
- Where
- United States
- When
- Starts or started Jan 2012, ends 15 April 2013. Registered 9 Aug 2012.
- Results
- None posted yet.
In the researchers' words
The investigators will assess the incidence of Overactive Bladder/Detrusor Overactivity (OAB/DO) post-operatively in patients post robotic assisted radical prostatectomy (RARP) and to investigate whether fesoterodine will alter the incidence of OAB/DO in these patients. Additionally, the correlation between OAB symptoms and urodynamic DO will be analyzed.
Sites
- Abramson Cancer Center of the University of PennsylvaniaPhiladelphia, Pennsylvania, United States